P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, NorwayECCO '18 Vienna
2018
P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitisECCO '18 Vienna
2018
P638: Nutritional status in paediatric Crohn’s disease patients: Does exclusive enteral nutrition help?ECCO '18 Vienna
2018
P639: Validation of the Quantum Blue® infliximab-level rapid test in clinical practice of patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P640: Risk of post-operative complications among Crohn’s disease patients treated pre-operatively with vedolizumab. A matched case–control studyECCO '18 Vienna
2018
P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)ECCO '18 Vienna
2018
P642: Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitisECCO '18 Vienna
2018
P643: Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patientsECCO '18 Vienna
2018
P644: Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD)ECCO '18 Vienna
2018
P645: Dynamics of proinflammatory cytokines in patients with Crohn's disease who received combined therapy with mesenchymal stromal cells of bone marrow and azathioprineECCO '18 Vienna
2018
P646: Refinement of surgical technique offsets increased severity of Crohn’s disease and co-morbidities to maintain low post-operative morbidityECCO '18 Vienna
2018
P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?ECCO '18 Vienna
2018
P648: Clinical feasibility of dried blood sampling for infliximab in IBD patientsECCO '18 Vienna
2018
P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?ECCO '18 Vienna
2018
P651: Reliability of blood tests, neutrophil lymphocyte ratio (NLR) and Glasgow prognostic index (GPI) to evaluate the severity of the Crohn’s diseaseECCO '18 Vienna
2018
P652: Nutritional adequacy of popular defined diets for inflammatory bowel diseaseECCO '18 Vienna
2018